Adial Pharmaceuticals, Inc. (NASDAQ:ADIL – Get Free Report) was the target of a significant decrease in short interest in October. As of October 15th, there was short interest totalling 51,200 shares, a decrease of 34.2% from the September 30th total of 77,800 shares. Based on an average daily volume of 253,200 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.8% of the shares of the company are short sold.
Adial Pharmaceuticals Price Performance
Shares of Adial Pharmaceuticals stock opened at $1.10 on Friday. Adial Pharmaceuticals has a 52-week low of $0.77 and a 52-week high of $4.17. The company’s fifty day moving average price is $1.02 and its two-hundred day moving average price is $1.24.
Adial Pharmaceuticals (NASDAQ:ADIL – Get Free Report) last posted its earnings results on Tuesday, August 13th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.20). As a group, research analysts anticipate that Adial Pharmaceuticals will post -1.62 EPS for the current year.
Institutional Investors Weigh In On Adial Pharmaceuticals
About Adial Pharmaceuticals
Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.
Read More
- Five stocks we like better than Adial Pharmaceuticals
- Investing in Commodities: What Are They? How to Invest in Them
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Technology Stocks Explained: Here’s What to Know About Tech
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- With Risk Tolerance, One Size Does Not Fit All
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Adial Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adial Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.